Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP)

Health Canada is aware of the growing interest in the use of psilocybin, including psilocybin that occurs naturally in certain mushroom species, for potential therapeutic purposes. In response, Health Canada is issuing this notice to provide information on the use of psilocybin mushrooms in clinical trials or as a drug requested through the Special Access Program (SAP), and to emphasize the importance of drug quality and Good Manufacturing Practices (GMP).

Data and Resources

Additional Info

Field	Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French)	Avis aux intervenants : Considérations concernant l’utilisation proposée des champignons à psilocybine dans les essais cliniques ou en tant que médicament auquel on accède par le biais du Programme d’accès spécial (PAS)
Update Frequency	as_needed
Geographic Scope	[]
Criticality Level	[]
Sensitivity Level	unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published	2022-05-04 00:00:00
Open Canada Date Modified
Open Canada Subject	["health_and_safety"]
Open Canada Keywords	{"fr": ["avis aux parties prenantes", "psilocybine", "espèces de champignons", "utilisation de la psilocybine", "programme d'accès spécial", "SAP", "médicament accessible via SAP"], "en": ["notice to stakeholders", "psilocybin", "mushroom species", "use of psilocybin", "special access program", "SAP", "drug accessed through-SAP"]}
Open Canada Collection	publication
Principal Organization
Reference Data
Official Source